文献速递肝病消化道肿瘤与早癌

乙醛脱氢酶2(ALDH2)通过调控AMP活化蛋白激酶信号通路抑制小鼠肝细胞癌进展

Aldehyde dehydrogenase-2 (ALDH2) opposes hepatocellular carcinoma progression by regulating AMP-activated protein kinase signaling in mice.
PubMed 文献 · Hepatology · 2017-03-31

研究在转录组和蛋白质组水平筛选与肝细胞癌发生及进展相关的功能基因,发现ALDH2在肿瘤组织中mRNA和蛋白水平显著低于正常组织,且与生存及转移相关临床病理特征相关。过表达或敲低实验显示ALDH2在体内外抑制迁移和侵袭,并通过调节乙醛水平改变细胞氧化还原状态、激活AMPK信号通路。结论认为ALDH2降低可能提示预后不良,强制表达可 largely 通过ALDH2-乙醛-氧化还原-AMPK轴抑制侵袭行为。

要点

  • ALDH2在肝细胞癌肿瘤组织中mRNA和蛋白水平显著低于正常组织,在迁移能力增强的组织中更低。
  • ALDH2与生存及转移、门静脉癌栓等多重迁移相关临床病理特征相关。
  • 过表达或敲低ALDH2在体内外抑制迁移和侵袭,并通过乙醛水平调控氧化还原状态、激活AMPK通路。

核心结论

  • ALDH2水平降低可能提示肝细胞癌患者预后不良,强制表达ALDH2在体外和小鼠中 largely 通过调控ALDH2-乙醛-氧化还原-AMPK轴活性抑制侵袭行为。
  • 识别肝细胞癌中ALDH2表达水平可能是对患者分类及开发针对转移性肝细胞癌的潜在治疗策略的有用方法。

研究设计与样本

  • 在转录组和蛋白质组水平筛选与肝细胞癌发生及进展相关的功能基因,鉴定ALDH2为进一步研究对象。
  • 通过过表达或敲低ALDH2在体内外评估其对迁移和侵袭的影响。

主要发现

  • ALDH2在肿瘤组织中mRNA和蛋白水平显著低于正常组织,在迁移能力增强的组织中更低。
  • ALDH2与生存及包括转移和门静脉癌栓在内的多重迁移相关临床病理特征相关。
  • 过表达或敲低ALDH2在体内外抑制迁移和侵袭。
  • ALDH2通过调节乙醛水平改变细胞氧化还原状态,并进一步激活AMPK信号通路。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Potential biomarkers that can be used to determine prognosis and perform targeted therapies are urgently needed to treat patients with hepatocellular carcinoma (HCC). To meet this need, we performed a screen to identify functional genes associated with hepatocellular carcinogenesis and its progression at the transcriptome and proteome levels. We identified aldehyde dedydrogenase-2 (ALDH2) as a gene of interest for further study. ALDH2 levels were significantly lower at the mRNA and protein level in tumor tissues than in normal tissues, and they were even lower in tissues that exhibited increased migratory capacity. A study of clinical associations showed that ALDH2 is correlated with survival and multiple migration-associated clinicopathological traits, including the presence of metastasis and portal vein tumor thrombus. The result of overexpressing or knocking down ALDH2 showed that this gene inhibited migration and invasion both in vivo and in vitro. We also found that ALDH2 altered the redox status of cells by regulating acetaldehyde levels and that it further activated the AMP-activated protein kinase (AMPK) signaling pathway. CONCLUSION: Decreased levels of ALDH2 may indicate a poor prognosis in HCC patients, while forcing the expression of ALDH2 in HCC cells inhibited their aggressive behavior in vitro and in mice largely by modulating the activity of the ALDH2-acetaldehyde-redox-AMPK axis. Therefore, identifying ALDH2 expression levels in HCC might be a useful strategy for classifying HCC patients and for developing potential therapeutic strategies that specifically target metastatic HCC. (Hepatology 2017;65:1628-1644).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Hou G, Chen L, Liu G, et al. Aldehyde dehydrogenase-2 (ALDH2) opposes hepatocellular carcinoma progression by regulating AMP-activated protein kinase signaling in mice. Hepatology. 2017. PMID: 28027570. doi:10.1002/hep.29006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。